Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes
D Owen, CH Chapman - Journal of Clinical Oncology, 2024 - ascopubs.org
The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …
Journal into clinical context. A case presentation is followed by a description of diagnostic …
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non …
JH Heinzerling, KF Mileham, MM Robinson… - The Lancet …, 2025 - thelancet.com
Background Patients with locally advanced non-small-cell lung cancer (NSCLC) who
undergo concurrent chemotherapy and radiotherapy often experience synergistic toxicity …
undergo concurrent chemotherapy and radiotherapy often experience synergistic toxicity …
Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis
GA Viani, AG Gouveia, AV Louie, F Arcidiacono… - Radiotherapy and …, 2024 - Elsevier
Introduction To evaluate the feasibility, efficacy and safety of stereotactic ablative
radiotherapy (SABR) to the primary tumor and lymph nodes in patients with locally advanced …
radiotherapy (SABR) to the primary tumor and lymph nodes in patients with locally advanced …
[HTML][HTML] Durvalumab impacts progression-free survival while high-dose radiation> 66 Gy improves local control without excess toxicity in unresectable NSCLC stage III …
F Zehentmayr, P Feurstein, E Ruznic, B Langer… - Radiotherapy and …, 2024 - Elsevier
Background Chemo-radioimmunotherapy with total radiation doses of 60–66 Gy in 2 Gy
fractions is the standard of care for non-small cell lung cancer (NSCLC) UICC stage III. The …
fractions is the standard of care for non-small cell lung cancer (NSCLC) UICC stage III. The …
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune …
K Hashimoto, D Morinaga, H Asahina… - JTO Clinical and …, 2024 - Elsevier
Introduction Oligometastasis and oligoprogression (OP) has not been adequately defined in
extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment …
extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment …
Multi-Center Prospective Phase Ii Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (Sbrt) Followed by Concurrent Mediastinal Chemoradiation and …
JH Heinzerling, KF Mileham, M Robinson, RR Induru… - papers.ssrn.com
Background: These are the efficacy and toxicity outcomes of a prospective phase II trial of
primary tumor stereotactic body radiation (SBRT) followed by conventional chemoradiation …
primary tumor stereotactic body radiation (SBRT) followed by conventional chemoradiation …
[HTML][HTML] Home Evolving Standards of Care Patterns of Failure after PACIFIC: How to Address Disease Recurrence after Chemoradiotherapy and Immunotherapy
CM Friedes, SJ Feigenberg, N Yegya-Raman - ilcn.org
The standard of care for patients with unresectable locally advanced non-small cell lung
cancer (NSCLC) is concurrent chemoradiotherapy followed by consolidative durvalumab, as …
cancer (NSCLC) is concurrent chemoradiotherapy followed by consolidative durvalumab, as …
2024 年度非小细胞肺癌放射治疗研究进展
**加冉， 袁双虎 - 肿瘤综合治疗电子杂志, 2025 - jmcm2018.com
2024 年度非小细胞肺癌(non-small cell lung cancer, NSCLC) 放射治疗(简称放疗)
领域取得了一系列进展, 为NSCLC 患者提供了更精准和个体化的治疗选择. 在早期NSCLC 中 …
领域取得了一系列进展, 为NSCLC 患者提供了更精准和个体化的治疗选择. 在早期NSCLC 中 …